HBXIP and LSD1 Scaffolded by lncRNA Hotair Mediate Transcriptional Activation by c-Myc

Li, Yinghui; Wang, Zhen; Shi, Hui; Li, Hang; Li, Leilei; Fang, Runping; Cai, Xiaoli; Liu, Bowen; Zhang, Xiaodong; Ye, Lihong

doi:10.1158/0008-5472.can-14-3607

Cited by 110 publications

(90 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HBXIP is commonly identified as an oncogene and exerts a profound effect on breast cancer. 89,90 A recent study has found that there was a strongly positive association between HBXIP and METTL3. 91 Overexpression of HBXIP could significantly elevate the expression of METTL3 in breast cancer tissues and vice versa.…”

Section: Mettl3mentioning

confidence: 99%

The dual role of N6‐methyladenosine modification of RNAs is involved in human cancers

Wang

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

As the most abundant and reversible RNA modification in eukaryotic cells, m6A triggers a new layer of epi‐transcription. M6A modification occurs through a methylation process modified by “writers” complexes, reversed by “erasers”, and exerts its role depending on various “readers”. Emerging evidence shows that there is a strong association between m6A and human diseases, especially cancers. Herein, we review bi‐aspects of m6A in regulating cancers mediated by the m6A‐associated proteins, which exert vital and specific roles in the development of various cancers. Generally, the m6A modification performs promotion or inhibition functions (dual role) in tumorigenesis and progression of various cancers, which suggests a new concept in cancer regulations. In addition, m6A‐targeted therapies including competitive antagonists of m6A‐associated proteins may provide a new tumour intervention in the future.

show abstract

Section: Mettl3mentioning

confidence: 99%

The dual role of N6‐methyladenosine modification of RNAs is involved in human cancers

Wang

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…Studies have shown that highly expressed HBXIP leads to the promotion of breast cancer development. 28,29 Herein, we evaluated the relationship between ZEB1 and HBXIP in regard to breast cancer malignancy. The levels of ZEB1 and HBXIP in clinical breast cancer samples were examined.…”

Section: Hbxip-upregulated Zeb1 Enhances Breast Cancer Cell Proliferamentioning

confidence: 99%

Oncogenic HBXIP enhances ZEB1 through Sp1 to accelerate breast cancer growth

et al. 2018

View full text Add to dashboard Cite

BackgroundThere is abundant evidence to indicate that HBXIP functions as an oncoprotein and transcription co‐activator during the development and promotion of cancers. In multiple cancers, ZEB1 serves as a transcription activator to regulate gene expression. We explored the roles of ZEB1 in HBXIP‐induced breast cancer growth.MethodsHBXIP regulation of ZEB1 was evaluated by reverse transcription PCR and immunoblotting. The stimulation of ZEB1 promoter by HBXIP and/or Sp1 was tested using luciferase reporter gene analysis. The alteration of cell proliferation mediated by HBXIP‐induced ZEB1 was tested using methyl‐thiazolyl‐tetrazolium and 5‐Ethynyl‐2′‐deoxyuridine (EdU) incorporation analysis. ZEB1 and HBXIP expression in human breast cancer tissues was analyzed using quantitative real‐time PCR. The relationship between HBXIP and ZEB1 was confirmed by Pearson's correlation coefficient.ResultsWe observed dose‐dependent upregulation of ZEB1 by HBXIP in breast cancer cells. HBXIP can activate the ZEB1 promoter by interacting with transcription factor Sp1. Cell viability and EdU incorporation analysis showed that HBXIP could drive cell proliferation by enhancing ZEB1 in breast cancer. Using quantitative real‐time PCR, ZEB1 overexpression and a positive relationship between ZEB1 and HBXIP were observed in clinical breast cancer samples.ConclusionOncogenic HBXIP controls the transcription regulation of ZEB1 by co‐activating Sp1, thereby accelerating breast cancer growth.

show abstract

“…As a regulatory member, HBXIP plays a pivotal role in the activation of mTORC1‐mediated by amino acid . Some studies have revealed that HBXIP can function as an oncogenic co‐activator of many transcription factors to play a key part in the transcription regulation of tumor‐related genes in breast cancer . However, whether HBXIP is involved in the effect of miR‐145 on breast cancer development remains unknown.…”

Section: Introductionmentioning

confidence: 99%

MiR‐145‐targeted HBXIP modulates human breast cancer cell proliferation

et al. 2018

View full text Add to dashboard Cite

BackgroundMiR‐145 has been identified as a tumor suppressive microRNA in multiple cancers. In this current investigation, we searched for new direct targets of miR‐145 and evaluated their effect on breast cancer development.MethodsTargetscan was used to predict the target genes of miR‐145. The targeting of miR‐145 on oncogenic HBXIP was verified by luciferase reporter gene analysis. The effect of miR‐145 on the level of messenger RNA and protein of HBXIP was evaluated by quantitative real‐time PCR and immunoblotting. Correlations between miR‐145 and HBXIP, as well as miR‐145 expression, were analyzed in 30 paired breast cancer and noncancerous tissues by quantitative real‐time PCR. Methyl thiazol tetrazolium and colony formation assays were applied to determine the cell proliferation ability.Results HBXIP was identified as a novel target gene of miR‐145 in breast cancer. MiR‐145 was found to dose‐dependently decrease messenger RNA and protein expression of HBXIP in breast cancer MCF‐7 cells. Notably, miR‐145 expression was negatively related to HBXIP expression and was obviously reduced in breast cancer samples. Finally, miR‐145 suppressed cell proliferation while its inhibitor, anti‐miR‐145, accelerated cell proliferation. Interestingly, silencing of HBXIP reversed the acceleration of cell proliferation induced by anti‐miR‐145 in breast cancer.ConclusionOncogenic HBXIP is a new direct target of tumor suppressive miR‐145. Our findings reveal that miR‐145‐targeting HBXIP could be a potential therapeutic target in breast cancer.

show abstract

HBXIP and LSD1 Scaffolded by lncRNA Hotair Mediate Transcriptional Activation by c-Myc

Cited by 110 publications

References 51 publications

The dual role of N6‐methyladenosine modification of RNAs is involved in human cancers

The dual role of N6‐methyladenosine modification of RNAs is involved in human cancers

Oncogenic HBXIP enhances ZEB1 through Sp1 to accelerate breast cancer growth

MiR‐145‐targeted HBXIP modulates human breast cancer cell proliferation

Contact Info

Product

Resources

About